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Managing the proteins that make up the content of a cellis central to assuring cellular viability and can affect
gene expression, cell cycle regulation, and ability to withstand
stress conditions. There are many components of the systems
that maintain protein homeostasis, including the proteasome,
which functions to degrade misfolded or unstable proteins,
the heat shock proteins (HSPs), which stabilize or “chaper-
one” misfolded proteins and work in conjuction with the
proteasome degradation pathway, and histone/chromatin
modulators, which modulate gene expression and also inter-
act with the protein degradation and chaperone systems. All
these are emerging targets for anticancer therapy, as their
inhibition disrupts the ability of cells to grow and divide.
Herein, we will review the key aspects of anticancer therapy
prospects within the protein degradation and chaperone sys-
tems discussed at the 2009 Santa Monica meeting, with a
focus on non-small cell lung cancer (NSCLC) therapy.
SUMMARY OF PRESENTATION
This section opened with an overview of the rationale
for targeting HSP 90. HSP-90 functions as a molecular
chaperone in that it helps maintain protein stability and
mediates the conformational maturity of its protein “clients,”
which include dozens of critical signaling proteins.1,2 Block-
ing HSP-90 function and enhancing degradation of its client
proteins is a rational strategy for anticancer therapy, facili-
tating the blockade of multiple signaling pathways simulta-
neously through a single drug. Furthermore, HSP-90 inhibi-
tion may preferentially be more potent within cancer cells
compared with normal tissue given the increased adenosine
triphosphatease activity in cancer cells and the increased
affinity of HSP90 for binding mutated clients over the cor-
responding wild-type proteins.3 In NSCLC models, there is
preclinical evidence that tumors with epidermal growth factor
receptor (EGFR) mutations may remain sensitive to HSP-90
inhibition even after acquiring resistance to EGFR tyrosine
kinase inhibitors (TKIs).4 Two intravenously administered
HSP-90 compounds in clinical development were discussed.
IPI-504 (Infinity Pharmaceuticals, Inc.) is a water-soluble
geldanamycin derivative that has been studied in several
clinical trials for patients with gastrointestinal stromal tumors
and is currently being tested in a multicenter phase II study
for patients with NSCLC previously treated with EGFR
TKIs. EGFR mutation status is being determined for all
patients in this trial and preliminary results will be reported at
American Society of Clinical Oncology 2009. The second
HSP-90 inhibitor discussed was AUY922 (Novartis), a non-
geldanamycin-based compound, which is in early phase I
clinical development.
Next, the session turned attention toward the ubiquitin-
proteasome system, which controls the degradation of pro-
teins through ubiquitination, a complexly regulated process
that attaches a chain of ubiquitin proteins to the target protein
and routes it toward the proteasome complex where it is disas-
sembled. The ubiquitin-proteasome system is a key therapeutic
target in cancer, because oncogenic mutations disrupt the normal
ubiquitination process and thereby influence control of cell
growth and death.5,6 Bortezemib (Velcade, Millenium Pharma-
ceuticals) is an Food and Drug Administration-approved intra-
venously administered proteasome inhibitor, and is widely used
in the treatment of multiple myeloma. It targets many aspects
of the proteasome complex, including p27, p53, NFkB, Bcl-2,
and Bax. Bortezemib has been studied in NSCLC in several
studies as a single agent, in combination with chemotherapy,
and in combination with EGFR TKIs. A small number of
patients on these trials have exhibited dramatic and/or sus-
tained responses, and ongoing investigation into this subset of
patients is aimed at trying to identify a predictive biomarker.
There may be a schedule or sequence dependency when
giving bortezemib with EGFR TKIs, but further research is
needed.7 Novel proteasome inhibitors and also therapies that
target the ubiquitin proteins directly are being developed but
remain in preclinical study and early clinical development at
this time.
Finally, histone deacetylase (HDAC) and its role as a
cancer target were discussed. HDAC is a key enzyme in-
volved in epigenetic regulation of gene expression, meaning
changes in the gene expression profile mediated by mecha-
nisms other than direct alteration of the gene sequence itself.
Epigenetic regulation includes alterations in the DNA meth-
ylation status, covalent modifications of core nucleosomal
histones, rearrangement of histones, and RNA interference.
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HDAC removes acetyl groups from histones, enabling them
to associate closely with DNA and preventing normal gene
expression and transcription regulation. Hence, HDAC inhib-
itors are emerging cancer therapeutic targets as they facilitate
the acetylation of histones, the relaxation of histones from the
DNA, and therefore the reactivation of transcription, differ-
entiation of cells, and apoptotic cell death.8,9 SAHA (Vori-
nostat, Merck) is an Food and Drug Administration-approved
orally administered HDAC inhibitor used in the treatment of
cutaneous T-cell lymphoma. It has been studied in NSCLC as
a single agent and in combination with chemotherapy and
seems most promising when used together with chemother-
apy. An ongoing randomized placebo-controlled phase III
trial is evaluating SAHA in combination with first-line che-
motherapy (carboplatin and paclitaxel). Newer oral agents in
this class include SNDX-275 (Entinostat, Syndax), which has
completed phase I studies as both a single agent and in
combination with erlotinib, 5-azacytadine and with 13-cis-
retinoic acid, and LBH-589 (Panobinostat, Novartis), which
is entering early clinical trials currently and may have activity
in small cell lung cancer.
SUMMARY AND FUTURE DIRECTIONS
In summary, targeting the protein degradation and chap-
erone systems is an exciting approach to cancer therapeutics.
Because of the central roles that protein homeostasis and epige-
netic regulation play in maintaining cell growth, metastasis,
angiogenesis, and other features of the cancer phenotype, their
disruption seems to hold promise for treating patients. Further
research must focus on establishing the safety and clinical
parameters of using these emerging therapeutics, developing
rational combinations with other targeted and chemotherapy
agents, and in defining a population of patients most likely to
respond to and benefit from treatment.
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